Androinz.reverse_treatment.1.var Apr 2026

Antiandrogen treatment can cause stromal cell reprogramming, leading to SPP1+ myCAFs (myofibroblastic cancer-associated fibroblasts) that create a microenvironment resistant to androgen deprivation therapy.

These truncated variants (like ARv567es) lack the ligand-binding domain but remain constitutively active, driving resistance to castration and newer antiandrogens. Androinz.Reverse_Treatment.1.var

Key findings regarding androgen-targeted therapy resistance: Androinz.Reverse_Treatment.1.var

Resistance is also mediated by non-canonical pathways, such as ROR-γ (retinoic acid receptor-related orphan receptor γ), which acts as a driver of AR expression in CRPC. Androinz.Reverse_Treatment.1.var